Previous close | 53.55 |
Open | 41.80 |
Bid | 41.55 |
Ask | 44.75 |
Strike | 85.00 |
Expiry date | 2024-09-20 |
Day's range | 41.80 - 41.80 |
Contract range | N/A |
Volume | |
Open interest | 15 |
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackJudge Threatens Trump With Jail Over Gag Order ViolationsAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]